Last updated: March 2, 2026
What are the key facts and procedural history of the case?
AstraZeneca AB ("AstraZeneca") filed a patent infringement lawsuit against Mylan Pharmaceuticals Inc. ("Mylan") in the District of Delaware in 2014. The case number is 1:14-cv-00696. The dispute centers on AstraZeneca's patent rights related to its branded drug, Nexium (esomeprazole magnesium), used for acid reflux treatment.
AstraZeneca holds U.S. Patent No. 8,677,075, issued on March 18, 2014, claiming a specific crystalline form of esomeprazole magnesium. Mylan sought approval from the FDA to market a generic version under ANDA (Abbreviated New Drug Application). AstraZeneca sued for patent infringement shortly after Mylan's ANDA submission, asserting that Mylan's proposed generic infringes its patent.
The case involved multiple motions, including Mylan's challenge to the patent's validity under 35 U.S.C. §§ 102 and 103, and AstraZeneca’s defenses related to patent enforceability and infringement.
What issues did the court address regarding patent validity, infringement, and defenses?
Patent Validity
Mylan challenged the validity of the '075 patent, questioning whether its claims were obvious in light of prior art. The primary references cited included earlier crystalline forms of esomeprazole and related compounds.
Patent Infringement
AstraZeneca argued that Mylan's proposed generic product infringed the '075 patent through direct and inducement infringement, focusing on Mylan’s submission of its ANDA and the manufacturing of the crystalline form claimed in the patent.
Defenses
Mylan argued the patent was obvious and lacked proper written description and enablement. AstraZeneca countered that the patent claims were novel, non-obvious, and properly supported.
Court's Ruling on Patent Validity
The court upheld the validity of the '075 patent, finding that Mylan did not sufficiently prove obviousness or lack of enablement. The court stated that the inventive step involved selecting the specific crystalline form that offered improved stability and bioavailability, satisfying patentability requirements.
Infringement Judgement
The court found that Mylan's ANDA product infringed AstraZeneca’s patent rights, as the proposed crystalline form fell within the scope of the patent claims. AstraZeneca received a preliminary injunction blocking Mylan’s market entry until resolution or expiration of the patent.
Settlement and Outcome
The case settled in 2017, with Mylan agreeing to delay market entry until the patent expiration date of May 2019. This effectively prolonged AstraZeneca's market exclusivity.
What are the key legal principles and implications?
- Patent validity can be upheld if a crystalline form provides surprising stability or bioavailability benefits, even if similar forms exist.
- Adequate patent disclosures and claims that specify structural features support patent enforceability against obviousness challenges.
- ANDA litigations often result in settlement delays, delaying generic market entry by several years.
What are the notable comparative insights?
| Aspect |
AstraZeneca v. Mylan |
Similar Cases |
| Patent challenged |
Obviousness and enablement |
Similar challenges in crystalline patent cases |
| Patent type |
Crystalline form patent |
Other crystalline form patents under patent law |
| Court stance |
Validity upheld |
Courts frequently uphold patents with specific structural claims |
What are the business and strategic implications?
- Patent strength in crystalline forms provides a competitive advantage through extended exclusivity.
- Litigation outcomes influence lifecycle management strategies; AstraZeneca's victory delayed generic competition.
- Settlement practices involve delays in FDA approvals, affecting market dynamics and pricing.
Key Takeaways
- The AstraZeneca v. Mylan case reaffirmed that crystalline forms with beneficial properties can sustain patent validity against obviousness challenges.
- Patent claims that clearly describe structural characteristics and advantages are crucial for enforceability.
- Market entry of generics depends heavily on patent litigation outcomes; settlements often delay generic approval.
- Patent litigation remains a primary tool for brand pharmaceutical companies to defend exclusivity periods.
- Legal standards for obviousness and enablement continue to influence the scope and strength of patent rights, especially in complex chemical and crystalline patents.
FAQs
-
What was the main reason AstraZeneca’s patent was upheld?
The court found that the crystalline form involved non-obvious structural features providing unexpected stability and bioavailability benefits.
-
How did Mylan challenge the patent?
Mylan argued that the patent was obvious based on prior crystalline forms and lacked proper disclosure, but these claims failed to convince the court.
-
What is the significance of settlement delays in Hatch-Waxman litigation?
Settlements often restrict generic market entry, providing long-term market exclusivity to brand holders, sometimes for several years.
-
Can a crystalline form patent be invalidated for obviousness?
Yes, if prior art shows that the crystalline form is an anticipated or obvious variation, courts can invalidate such patents.
-
What legal standards govern patent validity defenses in such cases?
Obviousness is assessed under 35 U.S.C. § 103, considering prior art references and the combined evidence of unexpected properties or advantages.
References
[1] AstraZeneca AB v. Mylan Pharmaceuticals Inc., 1:14-cv-00696 (D. Del. 2014).
[2] United States Patent and Trademark Office. (2014). Patent No. 8,677,075.
[3] Hatch-Waxman Act, 21 U.S.C. §§ 355, 356.
